该行认为，国际烟草巨头贯彻无烟化战略，菲莫Q1取得强劲开局，HNB增长符合预期、美国市场有序 推进，看好新型烟草供应链核心标的思摩尔国际。其中HNB 市场潜力仍然较大，且HNB较雾化烟在监 管上更占优(对青少年低吸引力、减害性更易论证)，竞争格局更好(参与厂商少)，同时英美烟草的新一 代Glo Hilo产品无论横向对比市面上的领军产品IQOS iluma i或是纵向对比上一代老产品均有显著的性能 和使用体验提升，看好其在25-26年逐渐拓展至更多市场、迎来放量，思摩尔做为GLO HILO核心供应 商，有望受益。 智通财经APP获悉，思摩尔国际(06969)涨超3%，截至发稿，涨2.36%，报13港元，成交额7316.81万港 元。 浙商证券发布研报称，4月23日，菲莫国际发布2025Q1业绩，IQOS作为HNB市场份额70%+的领军产 品，从其经营表现感知行业成长，对思摩尔的HNB业务潜力具备指导意义。25Q1菲莫国际SFP(Smoke- Free Products)收入同比+20.4%，毛利同比+33.1%，毛利率超过70%、同比提高6.7pct，且比传统烟高出 5pct；出货量同比+14.4%，其中HNB ...

截至2025年4月25日 09:35，恒生医疗保健指数(HSHCI)强势上涨1.77%，成分股医渡科技(02158)上涨10.15%，医脉通(02192)上涨7.05%，晶泰控股(02228)上 涨6.33%，云顶新耀-B(01952)，讯飞医疗科技(02506)等个股跟涨。恒生医疗ETF(513060)高开高走上涨2.68%，冲击5连涨。最新价报0.50元。拉长时间看， 截至2025年4月24日，恒生医疗ETF近1周累计上涨8.50%。 截至2025年4月18日，恒生医疗ETF近1年夏普比率为1.34。 回撤方面，截至2025年4月24日，恒生医疗ETF今年以来相对基准回撤0.45%，在可比基金中回撤最小。 费率方面，恒生医疗ETF管理费率为0.50%，托管费率为0.15%。 跟踪精度方面，截至2025年4月24日，恒生医疗ETF今年以来跟踪误差为0.042%，在可比基金中跟踪精度最高。 流动性方面，恒生医疗ETF盘中换手1.57%，成交1.83亿元。拉长时间看，截至4月24日，恒生医疗ETF近1月日均成交20.72亿元，居可比基金第一。 消息面上，4月24日，工业和信息化部等七部门关于印发《医药工业数智化 ...

Group 1 - The company, Boreton (01333.HK), plans to globally offer 13 million shares, with 1.3 million shares available in Hong Kong and 11.7 million shares for international sale, along with an over-allotment option of 1.95 million shares [1] - The subscription period for the shares is from April 25 to April 30, with a maximum offer price of HKD 18.00 per share, and an entry fee of approximately HKD 3,636.31 for a board lot of 200 shares [1] - The total expected fundraising amount is HKD 234 million, with a net amount of HKD 148 million, which will be used for establishing manufacturing facilities, purchasing necessary machinery, investing in technological advancements, developing new products and services, working capital, and expanding the sales and service network [1] Group 2 - The company has introduced cornerstone investors such as Hong Kong Xinwei Electronics Co., Ltd. and Changfeng Growth Open-Ended Fund, which will subscribe to approximately 3.5062 million shares at the offer price [1] - Boreton is expected to be listed on the main board on May 7, 2025, with China International Capital Corporation Hong Kong Securities Limited and CMB International Capital Limited serving as joint sponsors [1] - Boreton's business covers the entire clean energy production, storage, and utilization industry chain, providing integrated solutions for wind and solar energy management, hydrogen fuel and pure electric engineering machinery, mining trucks, heavy trucks, and unmanned driving innovations [1] Group 3 - The company's net profits for the years ending December 31 are projected to be -178 million, -229 million, and -275 million for 2022, 2023, and 2024 respectively, with year-on-year changes of -82.73%, -28.81%, and -19.67% [2]

【1】北京8所高校发布强基计划招生简章 4月24日，据"首都教育"微信公众号消息，近日，8所在京高校发布强基计划招生简章。与往年相比，前 沿技术专业的占比越来越重，部分高校新增机器人工程、人工智能、高分子材料等热门专业或方 向。"强基计划"致力于选拔培养有志于服务国家重大战略需求且综合素质优秀或基础学科拔尖的学生。 目前，有8所在京高校参加试点，分别为北京大学、清华大学、中国人民大学、北京师范大学、北京航 空航天大学、北京理工大学、中国农业大学和中央民族大学。 【2】北京昌平公布学科类校外培训机构"白名单" 4月24日，好未来公布2025财年第四季度及全年财务业绩。财报显示，2025财年全年净营收为22.5亿美 元，归属于好未来的净利润为8459.1万美元，上年同期净亏损为357.3万美元，同比扭亏为盈。 【5】凯文教育2024年净亏损3696.46万元 4月24日，凯文教育发布2024年年度报告，报告期内，凯文教育实现营业收入3.2亿元，较上年同期增长 25.92%，归属于上市公司股东的净利润亏损3696.46万元，较上年同期减亏25.66%。 【6】博骏教育2025财年中期业绩转亏 4月24日，博骏教育发 ...

中金：泡泡玛特(09992.HK)首季度国内外收入增长均胜预期 升目标价29%至220港元 金十数据4月25日讯，中金发表研报指，泡泡玛特(09992.HK)2025财年第一季预计收入按年增长165%至 170%，增速按季比较进一步提升。当中，中国(包括港澳台)收入按年增长95%至100%；海外市场收入 按年增长475%至480%，均超越该行及市场预期，主要由于中国国内同店表现优秀，以及海外热度高 企。中金提及，考虑到公司重点IP优质新品储备丰富、北美市场热度持续走高，故分别上调2025及2026 财年经调整净利润预测10%及8%，至分别64亿及79.2亿元人民币，同时上调目标价29%至220港元，相 当于预测今明两年经调整市盈率分别44倍及35倍，给予"跑赢行业"评级。 ...

智通财经APP获悉，中金发布研报称，考虑到付费用户增长好于预期，上调美图公司(01357)25年收入预 测2%至43亿元，考虑到收入结构占比变化，维持经调整净利润预测8.5亿元;考虑到订阅业务增长好于预 期，且有望带动毛利率提升，以及经营杠杆释放，上调26年收入和经调整净利润7%和13%至50和11亿 元。维持"跑赢行业"评级，给予31倍/24倍25和26年Non-IFRS P/E，维持目标价6.3港元。 中金主要观点如下： 近期，该行邀请美图管理层在2H24业绩后与投资人进行非交易性路演，公司分享了近期核心产品运营 情况，以及对长期业务发展的展望。该行预计25年订阅收入同增40%以上，系付费率和用户增长双轮驱 动： 1)国内生活类场景付费渗透好于预期 2)海外生活类场景用户规模增长加速 根据SensorTower，1Q以来，定位欧美日韩市场的Airbrush、BeautyPlus MAU较为稳定;AI换装等功能在 东南亚出圈，带动海外版Wink、美颜相机MAU环比大幅增长。受益于较高付费意愿和高级产品定位， 公司预计截至24年Airbrush付费率远高于国内，而其他出海产品还在积极扩张新市场阶段，短期尚未激 ...

截至发稿， 医渡科技(02158.HK)涨6.27%、景泰控股( 02228.HK)涨4.08%、 医脉通(02192.HK)涨 2.13%、 微创机器人-B(02252.HK)涨1.86%。消息方面，工信部等七部门印发《医药工业数智化转型实 施方案(2025-2030年)》提出，深化 人工智能赋能应用。支持相关单位建立医药大模型创新平台，协同 开展医药大模型技术产品研发、监管科学研究等，强化标准规范、科技伦理、应用安全和风险管理等规 则建设。 ...

Core Viewpoint - The report from CICC indicates a downward revision of FY25 EPS forecast for Chow Tai Fook (01929) by 7% to HKD 0.54, while maintaining FY26 EPS forecast at HKD 0.76 and introducing FY27 EPS forecast at HKD 0.83. The current stock price corresponds to 18/13/12 times FY25/26/27 P/E ratios, with a target price increase of 46% to HKD 11.41, corresponding to 15 times FY26 P/E [1]. Group 1 - The company reported a 11.6% year-on-year decline in overall retail value for 4QFY25, with declines of 10.4% in mainland China and 20.7% in Hong Kong and Macau [2]. - Same-store sales in mainland China and Hong Kong/Macau fell by 13.2% and 22.5% respectively [2]. - Despite the rising gold prices, mainland China business showed a sequential improvement, with retail value and same-store sales declining by 10.4% and 13.2% respectively, compared to previous quarter declines of 13.0% and 16.1% [3]. Group 2 - The company has made positive progress in channel upgrades and product innovation, opening 5 new concept stores in FY25, which have shown higher store efficiency and sales performance [4]. - New product lines, such as the Chuanfu series and the Palace Museum series, achieved sales exceeding HKD 4 billion each in FY25, reflecting the company's competitive strength in product design and innovation [4]. - The proportion of retail value from priced products surpassed 25% in the latest quarter, up from 9% in the same period last year, contributing to strong profitability [4]. Group 3 - For FY26, the company will continue to focus on improving store efficiency and product optimization, with a strategy to enhance same-store sales growth [5]. - The management plans to launch a new flagship product series, the Chuanxi series, in April 2025, and aims to increase the sales proportion of priced gold products to 20-23% in FY26 [5].

Group 1 - Hong Kong tech stocks saw a pre-market increase, with NetEase (09999.HK) and Bilibili (09626.HK) rising over 4% [1] - Alibaba (09988.HK) and Baidu (09888.HK) both increased by more than 2% [1] - Tencent Holdings (00700.HK) experienced a nearly 2% rise [1]

Core Viewpoint - China National Pharmaceutical Group's PD-1 monoclonal antibody, Anike (Paimupili injection), has received FDA approval for treating recurrent or metastatic nasopharyngeal carcinoma (NPC) as a first-line therapy and for patients who have failed platinum-based chemotherapy [1][2] Company Summary - Anike is the first innovative drug product from China National Pharmaceutical Group to be approved in the U.S. market [1] - The drug has already been approved for four indications in China, including first-line and subsequent treatment for advanced NPC, and two additional indications for lung cancer and Hodgkin lymphoma [1] - The FDA previously granted breakthrough therapy designation, orphan drug status, and fast track designation for Anike in treating NPC [2] - The CEO of China National Pharmaceutical Group emphasized that the U.S. approval reflects the alignment of China's innovative drug development with international standards and aims to provide new immunotherapy options for NPC patients globally [2] Industry Summary - In 2018, there were approximately 129,000 new cases of NPC globally, accounting for 0.7% of all cancer diagnoses [3] - Over 70% of NPC patients are diagnosed at an advanced stage, and those with recurrent/metastatic NPC have a poor prognosis, with a median overall survival of less than 20 months [3] - There is a significant unmet clinical need for effective treatments for advanced NPC patients [3]